Trospium Chloride Tablet, Film Coated
Product Images NDC 68462-461

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 68462-461). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

20mg Label

Label for Trospium Chloride Tablets USP 20 mg film-coated oral tablets. The package contains 60 tablets and is labeled for prescription use only. The label includes storage instructions, manufacturer information (Glenmark Pharmaceuticals Inc., USA), and a barcode.*

FDA Label Image

Figure 1

A pharmacokinetic plasma concentration versus time graph showing Trospium Chloride levels in ng/mL over 48 hours post-dose. Data points with error bars trace the concentration peak around 2-4 hours, followed by a gradual decline to near baseline by 48 hours.*

FDA Label Image

Figure 2

A line graph comparing the mean change over time (weeks 1, 4, and 12) between two groups: placebo (N=256) and Trospium chloride (N=253). The y-axis shows mean change with standard error, and the x-axis indicates weeks of treatment. The Trospium chloride group shows a greater decrease than the placebo group, with p-values indicating statistical significance at weeks 4 and 12.*

FDA Label Image

Figure 3

A line graph comparing mean (± standard error) changes over weeks of treatment for Trospium chloride versus placebo groups. The x-axis represents the week of treatment (1, 4, 12), and the y-axis shows mean change values. The graph includes p-values at each time point indicating statistical comparison between groups, with sample sizes for placebo (N=256) and Trospium chloride (N=253) noted in the legend.*

FDA Label Image

Figure 4

A line graph comparing the mean change from baseline over weeks of treatment between placebo and Trospium chloride groups. The x-axis shows treatment duration in weeks (1, 4, 12), and the y-axis shows mean change with standard error. Trospium chloride shows a greater decrease over time compared to placebo, with statistical significance indicated at each time point.*

FDA Label Image

Figure 5

A line graph depicting mean (± standard error) change over 12 weeks of treatment comparing Trospium chloride and placebo groups. The x-axis shows the weeks of treatment (1, 4, 12), and the y-axis shows mean change values. Two lines represent placebo (N=325) with higher mean change and Trospium chloride (N=323) with lower mean change, both showing statistically significant differences (p<0.001) at all time points.*

FDA Label Image

Glenmark Logo

FDA Label Image

Structure

Chemical structure of Trospium Chloride, illustrating its bicyclic structure with a quaternary ammonium ion linked to a benzhydryl ester group and a chloride counterion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.